Cabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: A possible association with inhibition of the vascular endothelial growth factor signaling pathway

European Journal of Dermatology

Volumn 23, Issue 2, 2013, Pages 274-275

  Cho, Yung Tsu ^a   Chan, Chih Chieh ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CISPLATIN; DOCETAXEL; ERLOTINIB; VASCULOTROPIN;

ADULT; ARTICLE; BLEEDING; BLISTER; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; CELL INCLUSION; CHEMORADIOTHERAPY; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHIL; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERKERATOSIS; HYPERTENSION; KERATINOCYTE; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; NAIL DISEASE; NECROSIS; PHYSICAL EXAMINATION; RASH; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN TINGLING; SKIN TOXICITY; SUBUNGUAL SPLINTER HEMORRHAGE; TREATMENT FAILURE;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HAND-FOOT SYNDROME; HEMORRHAGE; HUMANS; HYPERTENSION; LUNG NEOPLASMS; MIDDLE AGED; NAIL DISEASES; PYRIDINES;

EID: 84880961172     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.1930     Document Type: Article

References (7)

1. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 58: 592-6.
2. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 1411-6.
3. Robert C, Faivre S, Raymond E, et al. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Int Med 2005; 143: 313-34.
4. Kamba T, McDonald DM. Mechanisms of adverse effects of anti- VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-95.
5. Munehiro A, Yoneda K, Nakai K, et al. Bevacizumab-induced hand-foot syndrome: circumscribed type. Br J Dermatol 2010; 162: 1411-3.
6. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2: 289-300.
7. Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009:19:338-43.